(firstQuint)Pharmacokinetic and Pharmacodynamic Properties of BIOD-123 and BIOD-125 Compared to Humalog in Subjects With Type 1 Diabetes Including Assessments of Injection Site Toleration.

 The primary objective is to assess the speed of absorption of BIOD-123 and BIOD-125 and compare them to Humalog.

 The secondary objectives are to assess other pharmacokinetic characteristics of BIOD-123 and BIOD-125 and compare those to Humalog(R), to assess pharmacodynamic characteristics of BIOD-123 and BIOD-125 and compare those to Humalog(R), and to evaluate the safety and tolerability of BIOD-123 and BIOD-125 compared to Humalog(R).

 Pharmacokinetic and Pharmacodynamic Properties of BIOD-123 and BIOD-125 Compared to Humalog in Subjects With Type 1 Diabetes Including Assessments of Injection Site Toleration@highlight

The primary objective is to assess the speed of absorption of BIOD-123 and BIOD-125 and compare them to Humalog.

